Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D CompanyNot Yet RecruitingPhase 1
NCT07645222Not Yet Recruiting
Phase 1
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D Com...
NCT07646340
Long-term Pelvic Floor and Sexual Health After Obstetric Anal Sphincter Injury in FinlandTampere University HospitalEnrolling By Invitation
NCT07646340Enrolling By Invitation
—
Long-term Pelvic Floor and Sexual Health After Obstetric Anal Sphincter Injury i...Tampere University Hospit...
NCT07645547
Prophylactic Use of ciNPWT in Gynecologic LaparotomyUniversity Hospital Hradec KraloveNot Yet RecruitingNot Applicable
NCT07645547Not Yet Recruiting
Not Applicable
Prophylactic Use of ciNPWT in Gynecologic LaparotomyUniversity Hospital Hrade...
NCT07643961
Outpatient Versus Inpatient Management of Mild Acute PancreatitisCenter for Traumatology and Major Burns, Ben ArousNot Yet RecruitingNot Applicable
NCT07643961Not Yet Recruiting
Not Applicable
Outpatient Versus Inpatient Management of Mild Acute PancreatitisCenter for Traumatology a...
NCT07645716
Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic OncologyFondazione Policlinico Universitario Agostino Gemelli IRCCSNot Yet Recruiting
NCT07645716Not Yet Recruiting
—
Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards...Fondazione Policlinico Un...
NCT07645365
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialysis UnitAntalya Health Sciences UniversityCompleted
NCT07645365Completed
—
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialy...Antalya Health Sciences U...
NCT07643831
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast CancerGenentech, Inc.Unknown
NCT07643831Unknown
—
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2-...Genentech, Inc.
NCT07645768
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alternative to Conventional Posterior Double Plating in Extra-Articular Distal Shaft Humeral FracturesCairo UniversityActive Not RecruitingNot Applicable
NCT07645768Active Not Recruiting
Not Applicable
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alter...Cairo University
NCT07644741
Load-Matched Unilateral Versus Bilateral Squat Training in Elite Youth Futsal PlayersFederal University of VicosaCompletedNot Applicable
NCT07644741Completed
Not Applicable
Load-Matched Unilateral Versus Bilateral Squat Training in Elite Youth Futsal Pl...Federal University of Vic...
NCT07644442
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmedCompletedPhase 1
NCT07644442Completed
Phase 1
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmed
NCT07644039
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced MalignanciesPharmaMarRecruitingPhase 1
NCT07644039Recruiting
Phase 1
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advan...PharmaMar
NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaFred Hutchinson Cancer CenterNot Yet RecruitingPhase 1
NCT07645469Not Yet Recruiting
Phase 1
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Di...Fred Hutchinson Cancer Ce...
NCT07645495
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07645495Not Yet Recruiting
Not Applicable
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef University
NCT07646587
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants With Moderate - Severe COPDWindward BioRecruitingPhase 2
NCT07646587Recruiting
Phase 2
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants...Windward Bio
NCT07644312
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNationwide Children's HospitalNot Yet RecruitingPhase 2
NCT07644312Not Yet Recruiting
Phase 2
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG...Nationwide Children's Hos...
NCT07645170
Strain Counter-Strain vs Maitland Mobilization for Sacroiliac Joint PainUniversity of FaisalabadActive Not RecruitingNot Applicable
NCT07645170Active Not Recruiting
Not Applicable
Strain Counter-Strain vs Maitland Mobilization for Sacroiliac Joint PainUniversity of Faisalabad
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646314
Comparative Effects of Post-Isometric Relaxation and Reciprocal Inhibition Techniques inPiriformis SyndromeRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646314Not Yet Recruiting
Not Applicable
Comparative Effects of Post-Isometric Relaxation and Reciprocal Inhibition Techn...Riphah International Univ...
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07644949
Self-Help Plus (SH+) for Stress Reduction in Social Service Workers: A Pilot RCTIstanbul Medeniyet UniversityNot Yet RecruitingNot Applicable
NCT07644949Not Yet Recruiting
Not Applicable
Self-Help Plus (SH+) for Stress Reduction in Social Service Workers: A Pilot RCTIstanbul Medeniyet Univer...
Result Breakdown
Not yet recruiting10 (50%)
Completed3 (15%)
Recruiting3 (15%)
Active, not recruiting2 (10%)
Enrolling by invitation1 (5%)
Unknown1 (5%)
not_applicable8 (40%)
Not Specified5 (25%)
Phase 14 (20%)
Phase 23 (15%)